Tag Archive for: biotech

Ariceum Therapeutics announces granting of US and Canadian patents for its Gallium-68 radiopharmaceutical production kit

/in

Berlin, Germany, 6 December 2023 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the granting of US and Canadian patents covering its Gallium-68 (Ga-68) radiopharmaceutical production kit. The IP was developed by Theragnostics Ltd, which was acquired by Ariceum earlier […]

Read more

iOnctura to Present Research on Roginolisib and IOA-359 at ASH

/in

Three abstracts accepted by ASH with two poster presentations Geneva, Switzerland and Amsterdam, The Netherlands, 3 November 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San […]

Read more

STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer

/in

1 November 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce the appointment of Marguerite Hutchinson, J.D., as Chief Business Officer. Read more…

Read more

iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ

/in

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 31 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that the US Food and Drug Administration (FDA) has granted permission to proceed […]

Read more

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

/in

Invizius Limited (“Invizius”), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board. Read more…

Read more